7V3.F Cantargia AB (publ)

Healthcare Biotechnology Frankfurt Exchange
0.0992 EUR
Close of Nov 12, 2026
0.0846 0.5610
Market cap
EUR 28.0M
P/E
1.4x
P/B
1.22x
ROE
-49.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 7V3.F undervalued?

Graham number

The Graham number of Cantargia AB (publ) cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cantargia AB (publ) fundamental analysis

No fundamental analysis for Cantargia AB (publ) yet.

Cantargia AB (publ) stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cantargia AB (publ)

Cantargia AB (publ), a biotechnology company, develops pharmaceuticals for treatment of cancer, inflammatory, and autoimmune diseases. The company is developing CAN04 (nadunolimab), an monoclonal antibody that can bind IL1RAP, which is in phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in phase 1 clinical trial for the treatment of autoimmune and inf…

Full company profile